文献速递肿瘤 PET/CT骨显像与常规 SPECT

多发性骨髓瘤四肢骨骨髓定量新型低剂量CT方法的验证:GMMG-HD7三期试验[18F]FDG PET/CT子研究初步结果

Validation of novel low-dose CT methods for quantifying bone marrow in the appendicular skeleton of patients with multiple myeloma: initial results from the [18F]FDG PET/CT sub-study of the Phase 3 GMMG-HD7 Trial.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-10-01

结果显示两种CT方法均与骨髓浆细胞浸润、β2微球蛋白、长骨骨髓SUVmax及AI衍生的MTV/TLG等指标相关,诱导治疗后CT值显著下降。CT定量与MRD状态无显著关联。

要点

  • 手工CTv和半自动cCTv与骨髓浆细胞浸润、β2微球蛋白及PET代谢参数相关。
  • 长骨骨髓SUVmax与CTv强相关(r=0.61),与cCTv中度相关(r=0.45)。
  • 诱导治疗后CTv和cCTv较基线显著下降,CTv仍与长骨骨髓SUVmax相关。

核心结论

  • 基于低剂量CT的四肢骨骨髓定量方法与多发性骨髓瘤关键临床及PET参数相关,有望纳入骨髓瘤影像方案。

研究设计与样本

  • 患者在治疗前及诱导治疗后行全身[18F]FDG PET/CT,诱导方案为伊沙妥昔单抗联合来那度胺、硼替佐米和地塞米松或来那度胺、硼替佐米和地塞米松。
  • 采用MITK 2.4.0.0软件以手工法(CTv)和半自动法(cCTv)定量四肢骨骨髓浸润,PET数据按IMPeTUs标准视觉分析及SUV指标分析,并用AI方法自动导出全身MTV和TLG。
  • 诱导后所有患者用骨髓多参数流式细胞术评估MRD,影像数据与临床、组织病理、细胞遗传学参数及治疗反应进行相关性分析,统计学显著性定义为p<0.05。

主要发现

  • 基线中位CTv为26.1 HU,中位cCTv为5.5 HU。
  • CTv与骨髓浆细胞浸润相关(r=0.29;p=0.02),与β2微球蛋白相关(r=0.28;p=0.02);cCTv与骨髓浆细胞浸润相关(r=0.25;p=0.04)。
  • 长骨骨髓SUVmax与CTv强相关(r=0.61;p<0.001),与cCTv中度相关(r=0.45;p<0.001)。
  • 按IMPeTUs标准骨髓[18F]FDG摄取增高(Deauville评分≥4)的患者CTv和cCTv显著高于Deauville评分<4者(两者p=0.002)。
  • AI分析显示MTV与CTv相关(r=0.32;p=0.008)、与cCTv相关(r=0.45;p<0.001),TLG与CTv相关(r=0.36;p=0.002)、与cCTv相关(r=0.46;p<0.001)。

关键数值与推荐

  • PET/CT视觉分析采用意大利骨髓瘤PET应用标准(IMPeTUs),骨髓摄取增高定义为Deauville评分≥4。
  • 骨髓浆细胞浸润、β2微球蛋白、长骨骨髓SUVmax、MTV、TLG及Deauville评分作为参照指标与CT定量方法进行相关性比较。

临床怎么用

  • 低剂量CT四肢骨骨髓定量可作为多发性骨髓瘤影像方案的补充,辅助评估疾病范围和治疗反应。
  • CT定量结果需结合PET代谢参数(如长骨骨髓SUVmax、MTV、TLG)及临床指标综合解读。
  • CT定量与MRD状态无显著关联,不宜单独用于MRD评估。

局限性

  • CT定量方法与疾病负荷指标的相关性多为弱至中度。
  • 未报告CT定量与MRD状态之间的显著关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The clinical significance of medullary abnormalities in the appendicular skeleton detected by computed tomography (CT) in patients with multiple myeloma (MM) remains incompletely elucidated. This study aims to validate novel low-dose CT-based methods for quantifying myeloma bone marrow (BM) volume in the appendicular skeleton of MM patients undergoing [1⁸F]FDG PET/CT. MATERIALS AND METHODS: Seventy-two newly diagnosed, transplantation eligible MM patients enrolled in the randomised phase 3 GMMG-HD7 trial underwent whole-body [18F]FDG PET/CT prior to treatment and after induction therapy with either isatuximab plus lenalidomide, bortezomib, and dexamethasone or lenalidomide, bortezomib, and dexamethasone alone. Two CT-based methods using the Medical Imaging Toolkit (MITK 2.4.0.0, Heidelberg, Germany) were used to quantify BM infiltration in the appendicular skeleton: (1) Manual approach, based on calculation of the highest mean CT value (CTv) within bony canals. (2) Semi-automated approach, based on summation of CT values across the appendicular skeleton to compute cumulative CT values (cCTv). PET/CT data were analyzed visually and via standardized uptake value (SUV) metrics, applying the Italian Myeloma criteria for PET Use (IMPeTUs). Additionally, an AI-based method was used to automatically derive whole-body metabolic tumor volume (MTV) and total lesion glycolysis (TLG) from PET scans. Post-induction, all patients were evaluated for minimal residual disease (MRD) using BM multiparametric flow cytometry. Correlation analyses were performed between imaging data and clinical, histopathological, and cytogenetic parameters, as well as treatment response. Statistical significance was defined as p < 0.05. RESULTS: At baseline, the median CTv (manual) was 26.1 Hounsfield units (HU) and the median cCTv (semi-automated) was 5.5 HU. Both CT-based methods showed weak but significant correlations with disease burden indicators: CTv correlated with BM plasma cell infiltration (r = 0.29; p = 0.02) and β2-microglobulin levels (r = 0.28; p = 0.02), while cCTv correlated with BM plasma cell infiltration (r = 0.25; p = 0.04). Appendicular CT values further demonstrated significant associations with PET-derived parameters. Notably, SUVmax values from the BM of long bones were strongly correlated with both CTv (r = 0.61; p < 0.001) and moderately with cCTv (r = 0.45; p < 0.001). Patients classified as having increased [1⁸F]FDG uptake in the BM (Deauville Score ≥ 4), according to the IMPeTUs criteria, exhibited significantly higher CTv and cCTv values compared to those with Deauville Score <4 (p = 0.002 for both). AI-based analysis of PET data revealed additional weak-to-moderate significant associations, with MTV correlating with CTv (r = 0.32; p = 0.008) and cCTv (r = 0.45; p < 0.001), and TLG showing correlations with CTv (r = 0.36; p = 0.002) and cCTv (r = 0.46; p < 0.001). Following induction therapy, CT values decreased significantly from baseline (median CTv = -13.8 HU, median cCTv = 5.2 HU; p < 0.001 for both), and CTv significantly correlated with SUVmax values from the BM of long bones (r = 0.59; p < 0.001). In parallel, the incidence of follow-up pathological PET/CT scans, SUV values, Deauville Scores, and AI-derived MTV and TLG values showed a significant reduction after therapy (all p < 0.001). No significant differences in CTv, cCTv, or PET-derived metrics were observed between MRD-positive and MRD-negative patients. CONCLUSIONS: Novel CT-based quantification approaches for assessing BM involvement in the appendicular skeleton correlate with key clinical and PET parameters in MM. As low-dose, standardized techniques, they show promise for inclusion in MM imaging protocols, potentially enhancing assessment of disease extent and treatment response.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Sachpekidis C, Hajiyianni M, Grözinger M, et al. Validation of novel low-dose CT methods for quantifying bone marrow in the appendicular skeleton of patients with multiple myeloma: initial results from the [18F]FDG PET/CT sub-study of the Phase 3 GMMG-HD7 Trial. Eur J Nucl Med Mol Imaging. 2025. PMID: 41032077. doi:10.1007/s00259-025-07599-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。